Tuesday, December 02, 2025 9:55:32 PM
It wasn't intended for you Iron Mike. I don't know that it's true, but I've been told that bashers get additional pay for the responses they get, so I generally don't post directly back to them.
I know that you're a frustrated long, but you're a long and all of us are frustrated to at least some degree. I accept it, as I've been there before, so I'll support management as long as I believe that they too are looking for massive long-term growth. If LP doesn't sell the company, I believe in a decade or less the market cap can be well into triple digit billions. Given the current market cap, that's over 250 times its current market cap. Assuming substantial dilution we might see just over a 100 banger, few companies do better than that, and we just might do much better. If a decade from now both DCVax's are approved worldwide with tumor agnostic labels we might even be approaching the trillion-dollar market cap.
I don't know that we'll go there, but can you imagine where we'd be if most patients with serious cancers were getting one of the DCVax's as part of the SOC.
Gary
I know that you're a frustrated long, but you're a long and all of us are frustrated to at least some degree. I accept it, as I've been there before, so I'll support management as long as I believe that they too are looking for massive long-term growth. If LP doesn't sell the company, I believe in a decade or less the market cap can be well into triple digit billions. Given the current market cap, that's over 250 times its current market cap. Assuming substantial dilution we might see just over a 100 banger, few companies do better than that, and we just might do much better. If a decade from now both DCVax's are approved worldwide with tumor agnostic labels we might even be approaching the trillion-dollar market cap.
I don't know that we'll go there, but can you imagine where we'd be if most patients with serious cancers were getting one of the DCVax's as part of the SOC.
Gary
Bullish
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
